Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Influenza B Infections Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Influenza B Infections Overview | 9 | 1 |
| Pipeline Products for Influenza B Infections Comparative Analysis | 10 | 1 |
| Influenza B Infections Therapeutics under Development by Companies | 11 | 1 |
| Influenza B Infections Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Influenza B Infections Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Influenza B Infections Products under Development by Companies | 16 | 1 |
| Influenza B Infections Products under Investigation by Universities/Institutes | 17 | 1 |
| Influenza B Infections Companies Involved in Therapeutics Development | 18 | 13 |
| AbbVie Inc. | 18 | 1 |
| Altravax, Inc. | 19 | 1 |
| Aphios Corporation | 20 | 1 |
| BioClonetics Immunotherapeutics, Inc. | 21 | 1 |
| ContraFect Corporation | 22 | 1 |
| Humabs BioMed SA | 23 | 1 |
| Johnson &Johnson | 24 | 1 |
| Medicago Inc. | 25 | 1 |
| MedImmune, LLC | 26 | 1 |
| Mucosis B.V. | 27 | 1 |
| Sanofi Pasteur SA | 28 | 1 |
| Vaxart, Inc. | 29 | 1 |
| Zydus Cadila Healthcare Limited | 30 | 1 |
| Influenza B Infections Therapeutics Assessment | 31 | 9 |
| Assessment by Monotherapy Products | 31 | 1 |
| Assessment by Combination Products | 32 | 1 |
| Assessment by Target | 33 | 2 |
| Assessment by Mechanism of Action | 35 | 1 |
| Assessment by Route of Administration | 36 | 2 |
| Assessment by Molecule Type | 38 | 2 |
| Drug Profiles | 40 | 26 |
| AL-18 Drug Profile | 40 | 1 |
| APP-0205 Drug Profile | 41 | 1 |
| APP-309 Drug Profile | 42 | 1 |
| CF-403 Drug Profile | 43 | 1 |
| CR-8033 Drug Profile | 44 | 1 |
| CR-8071 Drug Profile | 45 | 1 |
| CR-9114 Drug Profile | 46 | 1 |
| Fluad (quadrivalent) Drug Profile | 47 | 1 |
| FluGEM Drug Profile | 48 | 1 |
| influenza [serotype B] vaccine Drug Profile | 49 | 1 |
| influenza [serotypes A, B] (split virion, tetravalent) vaccine Drug Profile | 50 | 1 |
| influenza [serotypes A, B] (virus like particle) vaccine Drug Profile | 51 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine Drug Profile | 52 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine Drug Profile | 53 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine Drug Profile | 54 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine Drug Profile | 55 | 3 |
| influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine Drug Profile | 58 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine Drug Profile | 59 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine Drug Profile | 60 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile | 61 | 1 |
| influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile | 62 | 1 |
| Monoclonal Antibody for Influenza B Drug Profile | 63 | 1 |
| Monoclonal Antibody for Influenza B Infections Drug Profile | 64 | 1 |
| VXABYW-10 Drug Profile | 65 | 1 |
| Influenza B Infections Dormant Projects | 66 | 1 |
| Influenza B Infections Discontinued Products | 67 | 1 |
| Influenza B Infections Product Development Milestones | 68 | 2 |
| Featured News &Press Releases | 68 | 1 |
| Dec 17, 2015: Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial | 68 | 1 |
| Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine | 69 | 1 |
| Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children | 69 | 1 |
| Appendix | 70 | 2 |
| Methodology | 70 | 1 |
| Coverage | 70 | 1 |
| Secondary Research | 70 | 1 |
| Primary Research | 70 | 1 |
| Expert Panel Validation | 70 | 1 |
| Contact Us | 70 | 1 |
| Disclaimer | 71 | 1 |